SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer
Open Access
- 4 March 2025
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (8)
Abstract
It is well documented that impaired DNA damage repair (DDR) induces genomic instability that can efficiently increase the sensitivity of prostate cancer (PCa) cells to PARP inhibitors; however, the underlying mechanism remains elusive. Here, we found profound genomic instability in PCa cells with SPOP gene mutations and confirmed the sensitivity of SPOP -mutated PCa cells to olaparib-induced apoptosis. Mechanistically, we identified olaparib-induced CK2-mediated phosphorylation of PIAS1-S468, which in turn mediated SUMOylation of SPOP, thus promoting its E3 ligase activity in the DDR. Moreover, an abnormal CK2/PIAS1/SPOP axis due to SPOP mutations or defects in CK2-mediated phosphorylation of PIAS1, as well as SPOP inhibitor treatment, led to impaired DDR, thus increasing olaparib-induced apoptosis of PCa cells and enhancing olaparib sensitivity in animal models and patient-derived organoids. This suggested that disruption of the CK2/PIAS1/SPOP signaling axis could serve as an indicator for targeted therapy of PCa using a PARP inhibitor.Keywords
Funding Information
- National Natural Science Foundation of China (32270821)
- the National Natural Science Foundation of Zhejiang (LY24C050001)
- the National Natural Science Foundation of Zhejiang (LTGY24H160005)
- The Youth Science and Technology Innovation Leader of Ningbo (2023QL052)
- K. C. Wong Magna Fund in Ningbo University (Not Applicable)
- The Ningbo Clinical Research Center for Urological Disease (2019A21001)
- the Ningbo Top Medical and Health Research Program (2022020203)
- Zhejiang Engineering Research Center of Innovative technologies and diagnostic and therapeutic equipment for urinary system diseases (Not Applicable)
This publication has 46 references indexed in Scilit:
- The predictive significance of chromobox family members in prostate cancer in humansCellular Oncology, 2024
- Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genesAnnals of Oncology, 2024
- The SUMOylation and ubiquitination crosstalk in cancerJournal of Cancer Research and Clinical Oncology, 2023
- Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 studyHepatology, 2023
- Molecular features and race‐associated outcomes of SPOP ‐mutant metastatic castration‐resistant prostate cancerThe Prostate, 2023
- Clinical and genomic features of SPOP‐mutant prostate cancerThe Prostate, 2021
- Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevanceCellular Oncology, 2020
- Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancerAsian Journal of Urology, 2020
- Cullin 3 and Its Role in Tumorigenesis2020
- TRIM24 Is an Oncogenic Transcriptional Activator in Prostate CancerCancer Cell, 2016